



## Procaps Group to Participate at BTG 2023 LatAm CEO Conference and Roth 2023 Healthcare Opportunities Conference in October

September 15, 2023

MIAMI & BARRANQUILLA, Colombia--(BUSINESS WIRE)--Sep. 15, 2023-- Procaps Group, S.A. (NASDAQ: PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical services company, announced today that members of its executive leadership team will participate at two upcoming investor conferences.

On October 5, 2023, the Company will attend BTG's 2023 LatAm CEO Conference in New York and will be available for investor meetings.

On October 12, 2023, the Company will present at Roth's 2023 Healthcare Opportunities Conference, in New York and will be available for investor meetings.

For more information on the BTG 2023 LatAm CEO Conference or Roth 2023 Healthcare Opportunities Conference, or to schedule an investor meeting with Procaps management, please contact your conference representative or you may also email your request to [ir@procapsgroup.com](mailto:ir@procapsgroup.com).

### About Procaps Group

Procaps (NASDAQ: PROC) is a leading developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies that reach more than 50 countries on five continents. Procaps has a direct presence in 13 countries in the Americas and more than 5,500 employees working under a sustainable model. Procaps develops, manufactures, and markets over-the-counter (OTC) pharmaceutical products, prescription pharmaceutical drugs (Rx), nutritional supplements, and high-potency clinical solutions.

For more information, visit [www.procapsgroup.com](http://www.procapsgroup.com) or Procaps' investor relations website [investor.procapsgroup.com](http://investor.procapsgroup.com).

### Forward Looking Statements

This press release includes "forward-looking statements." Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include projected financial information as well as the benefits (if any) to be achieved by our agreement with BDR Pharmaceuticals, and there can be no assurance that any regulatory approvals for the molecules underlying the agreement with BDR Pharmaceuticals will be obtained. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward-looking statements. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risks included under the header "Risk Factors" in Procaps' annual report on Form 20-F filed with the SEC, as well as Procaps' other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20230915200660/en/): <https://www.businesswire.com/news/home/20230915200660/en/>

### Investor Contact:

Melissa Angelini

[ir@procapsgroup.com](mailto:ir@procapsgroup.com)

+1 754 260-6476

[investor.procapsgroup.com](http://investor.procapsgroup.com)

Source: Procaps Group, S.A.